Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYNCAR 001

Next Previous
X
Search
Drug Profile

SYNCAR 001

Alternative Names: Orthogonal IL-2 receptor-modified CD-19 targeted CAR-T - Synthekine; STK 009/SYNCAR 001; STK-009 + SYNCAR-001; SYNCAR-001

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthekine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Interleukins; Urologics
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological malignancies; Lupus nephritis; Systemic lupus erythematosus
  • No development reported Cancer; Lymphoma

Most Recent Events

  • 09 Dec 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Haematological malignancies released by Synthekine
  • 04 Sep 2024 SYNCAR 001 receives Fast track status from the US FDA for Systemic lupus erythematosu
  • 01 Sep 2024 Phase-I clinical trials in Lupus nephritis in USA (Parenteral)(NCT06544330)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top